Abstract
Over the past decades, a tremendous rise in invasive fungal infection diseases attributed to the
yeast Candida albicans in immunocompromised individuals poses a seriously challenging issue. Another
concern is the emergence of multi-drug resistant pathogens to the existing medicines due to their overuse
and misuse. It was recently reported that 25-55% of the mortality rate is caused by invasive infection.
Despite a large variety of drugs being available to treat invasive candidiasis, only two of them contain a
1,2,4-triazole core, namely Fluconazole and itraconazole, which are efficient in treating infection induced
by fungal Candida species. Moreover, long-term therapy associated with azole medications has led to an
increase in azole resistance as well as a high risk of toxicity. Despite numerous outstanding achievements
in antifungal drug discovery, development of novel, safer and potent antifungal agents while overcoming
the resistance problem associated with the current drugs is becoming the main focus of medicinal chemists.
Therefore, this review outlines the breakthroughs in medicinal chemistry research regarding 1,2,4-
triazole-based derivatives as potential antifungal agents in the past decade. In addition, the structureactivity
relationship of these compounds is also discussed.
Keywords:
Triazole, Fungal infection, Candidiasis, Drug-resistant, Antifungal, Structure-activity relationship.
Graphical Abstract
[12]
Arikan, S.; Rex, J.H. Nystatin LF (Aronex/Abbott). Current opinion in investigational drugs (London, England : 2000), 2001, 2(4), 488-495.
[40]
Pfaller, M.; Chaturvedi, V.; Espinel-Ingroff, A.; Ghannoum, M.; Gosey, L.L.; Odds, F.C. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard second edition. CLSI document M27-A2 (ISBN 1-56238-469- 4).Clin Lab Stand Inst; , , 2008; 22, pp. 1-51.
[71]
Pagniez, F.; Le Pape, P. New fluorometric screening test for possible antifungal drugs. J. Med. Mycol., 2001, 11, 73-78.
[76]
Sorbera, L.; Bartroli, J.; Castañer, J. Albaconazole. Drugs of The Future - DRUG FUTURE, 2003, 28(6), 529-537.
[94]
Mackie, T.J.; McCartney, J.E.; Collee, J.G.; Mackie, T.J. Mackie & McCartney practical medical microbiology; Elsevier: Amsterdam, 1989.
[95]
Goyal, P.K.; Bhandari, A.; Rana, A.C.; Jain, C.B. Synthesis of some 3-substituted -4h-1, 2, 4-triazole derivatives with potent anti-inflammatory activity. Asian J. Pharma. Clin. Res., 2010, 3, 244-246.
[98]
Ahirwar, D.L.S.; Jha, K. Synthesis and characterization of 1,2,4-triazole- pyridine hybrids as potential antimicrobial agents. Intl. J. Pharma. Clin. Res., 2017, 9(12), 702-709.
[106]
Frolova, Y. Design, synthesis, antimicrobial and antifungal activities of new 1,2,4-triazole derivatives containing 1h-tetrazole moiety. Ankara Universitesi Eczacilik Fakultesi Dergisi, 2020, 70-88.
[111]
Gomha, S.; Edrees, M.; Muhammad, Z.; Kheder, N.; Melha, S.; Saad, A. Synthesis, characterization, and antimicrobial evaluation of some new 1,4-dihydropyridines-1,2,4-triazole hybrid compounds; Polycyc. Aromatic Compounds, 2020, pp. 1-13.